Gao Wei, Guo Zhi, Zhang Xuening, Wang Ying, Zhang Weihao, Yang Xueling, Yu Haipeng
*Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, People's Republic of China; and †Department of Radiology, Second Affiliated Hospital of Tianjin Medical University, Tianjin, People's Republic of China.
Int J Gynecol Cancer. 2015 Jun;25(5):802-8. doi: 10.1097/IGC.0000000000000420.
To evaluate the feasibility, safety, and effectiveness of percutaneous cryoablation for the treatment of liver metastases from ovarian cancer.
METHODS/MATERIALS: A retrospective review was performed on 13 patients with liver metastases from ovarian cancer who underwent percutaneous cryoablation with computed tomography (CT) guidance. The tumor response was assessed by enhanced computed tomography performed before treatment, 1 month after, and every 3 months after treatment. The Functional Assessment of Cancer Therapy-General quality of life (QOL) was used to assess the patients' QOL before, 1 week, 1 month, and 3 months after cryoablation.
A total of 27 procedures of cryoablation were performed on these patients, and 5 patients underwent repeat procedures. Complete ablation was achieved for all lesions. Months are counted from the time of cryoablation, and the median duration of follow-up was 15 months (4-22 months). At the 1-month follow-up, the primary technique effectiveness was 100%. At the 3-month follow-up, local tumor progression was observed in 2 (7.14%) of 28 lesions. The 1-year survival from the time of cryoablation was 92.3%. Two patients died after 9 and 14 months, respectively. The QOL symptoms and functioning scales were preserved in patients alive at 3 months after cryoablation. No major complications such as cryoshock, hepatic bleeding, liver abscess, biliary fistula, and renal insufficiency were encountered.
Our initial experience showed that cryoablation is a safe and effective ablative therapy, providing a high rate of local tumor control in ovarian cancer liver metastases.
评估经皮冷冻消融治疗卵巢癌肝转移的可行性、安全性及有效性。
方法/材料：对13例接受计算机断层扫描（CT）引导下经皮冷冻消融治疗的卵巢癌肝转移患者进行回顾性分析。通过治疗前、治疗后1个月及治疗后每3个月进行的增强计算机断层扫描评估肿瘤反应。采用癌症治疗功能评估通用生活质量（QOL）量表评估患者在冷冻消融前、后1周、1个月及3个月的生活质量。
这些患者共接受了27次冷冻消融治疗，5例患者接受了重复治疗。所有病灶均实现完全消融。随访时间从冷冻消融时开始计算，中位随访时间为15个月（4 - 22个月）。在1个月随访时，主要技术有效性为100%。在3个月随访时，28个病灶中有2个（7.14%）出现局部肿瘤进展。从冷冻消融时起的1年生存率为92.3%。2例患者分别在9个月和14个月后死亡。冷冻消融后3个月存活的患者其生活质量症状和功能量表得分保持稳定。未出现冷冻休克、肝出血、肝脓肿、胆瘘和肾功能不全等严重并发症。
我们的初步经验表明，冷冻消融是一种安全有效的消融治疗方法，在卵巢癌肝转移中能实现较高的局部肿瘤控制率。
